학술논문
A case of high‐risk AML in a patient with advanced systemic mastocytosis
Document Type
article
Author
Source
Clinical Case Reports, Vol 11, Iss 7, Pp n/a-n/a (2023)
Subject
Language
English
ISSN
2050-0904
Abstract
Abstract Aggressive SM + AML has limited therapeutic options. Even a strong combination of decitabine–venetoclax–midostaurin has a transient effect on AML and a mitigated effect on SM. Larger series are required to identify the best therapeutic strategy.